Compare SMHI & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMHI | PLX |
|---|---|---|
| Founded | 1989 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 212.7M | 182.9M |
| IPO Year | 2016 | 1996 |
| Metric | SMHI | PLX |
|---|---|---|
| Price | $9.45 | $2.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 121.9K | ★ 569.9K |
| Earning Date | 04-29-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.41 | N/A |
| EPS | N/A | ★ 0.22 |
| Revenue | ★ $173,783,000.00 | $52,744,000.00 |
| Revenue This Year | $1.21 | $36.81 |
| Revenue Next Year | $9.31 | N/A |
| P/E Ratio | ★ N/A | $10.77 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.55 | $1.46 |
| 52 Week High | $9.70 | $3.19 |
| Indicator | SMHI | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 68.78 | 61.47 |
| Support Level | $6.89 | $2.06 |
| Resistance Level | N/A | $3.03 |
| Average True Range (ATR) | 0.39 | 0.10 |
| MACD | 0.17 | -0.00 |
| Stochastic Oscillator | 92.41 | 94.68 |
Seacor Marine Holdings Inc provides marine and support transportation services to offshore energy facilities globally. The company operates and manages a diverse fleet of offshore support vessels that (i) deliver cargo and personnel to offshore installations, including offshore wind farms, (ii) assist offshore operations for production and storage facilities, (iii) provide construction, well work-over, offshore wind farm installation and decommissioning support and (iv) carry and launch equipment used underwater in drilling and well installation, maintenance, inspection and repair. Its geographical segment includes the United States (Gulf of Mexico), Africa and Europe, Middle East and Asia, and Latin America, with the majority of revenue deriving from the Africa and Europe segment.
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.